Soliton: A Reg A+, PR Machine With Lockup Expiry Next Week - $6 2-Week Price Target

Soliton (SOLY) had a recent Reg A+ IPO in February 2019, with an unproven device that is supposed to assist a laser with tattoo and cellulite removal. SOLY is a relentless PR machine that we believe will end very badly for shareholders who think they are holding a solid investment. The company has put out 17 PRs since the beginning of March. This PR campaign has worked, as the stock has risen from $4.99 on March 1st to a peak of $15, to over $10 today. We don't believe the PRs show any new important developments of the company. They just get people to buy shares.

Soliton posts on Twitter, Stocktwits and solicits Facebook fans in its PRs. The company is years from having an FDA approved product. Right now, they don't even have a finished product to submit to the FDA. The company claims in their PRs to have over 200K "fans". So what are these people fans of? Oh yeah, the stock! In our opinion, the company's real product is its stock.

Original source

Add comment

Please Sign in to be able to leave comments.